+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Indapamide Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148011
Global Indapamide Market Size, Share & Trends Analysis Report by Product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.

The global indapamide market is estimated to grow significantly at a CAGR of over 2.0% during the forecast period. A significant rise in the incidences of high blood pressure (hypertension) and congestive heart failure is primarily contributing to the growth of the market. High blood pressure affects approximately a third of the adult population across the globe and is the most common cause of CVD-related mortalities. As per the data published by the American Health Association (AHA) in January 2018, 103 million US adults were suffering from high blood pressure, which is nearly half of all adults in the US.

The global indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to the segmental growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

Geographically, the study of the global indapamide market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. The companies which are contributing to the growth of the global indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Krka Group, Glenmark Pharmaceuticals Ltd, Les Laboratoires Servier, SAS, Sandoz International Gmbh (A Novartis Division), Taj Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd. Various growth strategies are adopted by the market players to expand their market share and gain a competitive advantage. For instance, in January 2020, ANI Pharmaceuticals, Inc., acquired the US portfolio of 23 generic products from Amrigen Pharmaceuticals Ltd.

Research Methodology:

The market study of the global indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for indapamide market players, pharmaceutical companies, drug manufacturers, government organizations, regulatory bodies, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Indapamide Market Research and Analysis by Product
2. Global Indapamide Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the global indapamide market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global indapamide market.
  • Insights about market determinants which are stimulating the global indapamide market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Servier Group
3.1.2. Mylan N.V.
3.1.3. Krka Group
3.1.4. ANI Pharmaceuticals, Inc.
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints/Challenges
4.3. Opportunities
5. Market Segmentation
5.1. Global Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. Global Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. ANI Pharmaceuticals, Inc.
7.2. Apotex Inc.
7.3. BioindustriaL.I.M. S.p.A.
7.4. Glenmark Pharmaceuticals Ltd.
7.5. Grupo Azevedos
7.6. Krka Group
7.7. Laboratori Baldacci S.p.A.
7.8. Merck KGaA
7.9. Mylan N.V.
7.10. Preferred Pharmaceuticals, Inc
7.11. Sandoz International GmbH
7.12. SanisHealth Inc.
7.13. Sanofi S.A.
7.14. ServierGroup
7.15. Shandong Yinfeida Pharmaceutical Co., Ltd.
7.16. Supra Chemicals
7.17. Suzhou Lixin Pharmaceutical Co., Ltd.
7.18. Taj Pharmaceuticals Ltd.
7.19. Teva Pharmaceuticals Industries Ltd.
7.20. Torrent Pharmaceuticals Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ANI Pharmaceuticals, Inc.
  • Apotex Inc.
  • BioindustriaL.I.M. S.p.A.
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Azevedos
  • Krka Group
  • Laboratori Baldacci S.p.A.
  • Merck KGaA
  • Mylan N.V.
  • Preferred Pharmaceuticals, Inc
  • Sandoz International GmbH
  • SanisHealth Inc.
  • Sanofi S.A.
  • ServierGroup
  • Shandong Yinfeida Pharmaceutical Co., Ltd.
  • Supra Chemicals
  • Suzhou Lixin Pharmaceutical Co., Ltd.
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Torrent Pharmaceuticals Ltd.